DCF Advisers LLC Acquires 251,511 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

DCF Advisers LLC raised its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 87.2% in the 4th quarter, Holdings Channel reports. The firm owned 539,989 shares of the company’s stock after purchasing an additional 251,511 shares during the quarter. Lifecore Biomedical accounts for 1.9% of DCF Advisers LLC’s holdings, making the stock its 17th biggest holding. DCF Advisers LLC’s holdings in Lifecore Biomedical were worth $4,012,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Lifecore Biomedical by 10.3% during the third quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock worth $2,948,000 after purchasing an additional 55,703 shares during the last quarter. State Street Corp lifted its position in shares of Lifecore Biomedical by 10.2% during the third quarter. State Street Corp now owns 334,360 shares of the company’s stock worth $1,648,000 after purchasing an additional 30,916 shares during the last quarter. 272 Capital LP lifted its position in shares of Lifecore Biomedical by 511.1% during the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after purchasing an additional 120,002 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Lifecore Biomedical by 71.9% in the fourth quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock valued at $599,000 after acquiring an additional 33,690 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Lifecore Biomedical by 23.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 74,427 shares of the company’s stock valued at $553,000 after acquiring an additional 13,922 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lifecore Biomedical

In other Lifecore Biomedical news, CEO Paul Josephs purchased 17,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were acquired at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 32.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LFCR shares. Stephens restated an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum lifted their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Price Performance

LFCR opened at $6.58 on Friday. The business’s 50-day moving average is $6.11 and its two-hundred day moving average is $6.10. Lifecore Biomedical, Inc. has a 1 year low of $3.68 and a 1 year high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The firm has a market capitalization of $243.62 million, a PE ratio of -11.75 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Research analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.